Spots Global Cancer Trial Database for bruton tyrosine kinase inhibitor
Every month we try and update this database with for bruton tyrosine kinase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | NCT02972840 | Lymphoma, Mantl... | Acalabrutinib Bendamustine Rituximab Placebo | 65 Years - | Acerta Pharma BV | |
| Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | NCT02180711 | Non Hodgkin Lym... | acalabrutinib rituximab (IV) Lenalidomide | 18 Years - | Acerta Pharma BV | |
| A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole | NCT04564040 | Mantle Cell Lym... COVID-19 | Acalabrutinib T... Acalabrutinib T... Acalabrutinib T... Acalabrutinib T... | 18 Years - 55 Years | AstraZeneca | |
| An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | NCT02180724 | Waldenström Mac... | Acalabrutinib (... Acalabrutinib (... | 18 Years - 130 Years | Acerta Pharma BV | |
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | NCT02972840 | Lymphoma, Mantl... | Acalabrutinib Bendamustine Rituximab Placebo | 65 Years - | Acerta Pharma BV | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | NCT02972840 | Lymphoma, Mantl... | Acalabrutinib Bendamustine Rituximab Placebo | 65 Years - | Acerta Pharma BV | |
| An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | NCT02213926 | Mantle Cell Lym... | ACP-196 (acalab... | 18 Years - 130 Years | Acerta Pharma BV | |
| REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy | NCT05621148 | CLL, Relapsed CLL, Refractory Bruton Tyrosine... Small Lymphocyt... | 18 Years - | French Innovative Leukemia Organisation | ||
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole | NCT04564040 | Mantle Cell Lym... COVID-19 | Acalabrutinib T... Acalabrutinib T... Acalabrutinib T... Acalabrutinib T... | 18 Years - 55 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
